Effect of spironolactone in resistant arterial hypertension

Medicine (United States)

Volumn 93, Issue 27, 2014, Pages

  Václavík, Jan ^a   Sedlák, Richard ^b   JarkovskÝ, Jiří ^c   Kociánová, Eva ^a   TáborskÝ, Miloš ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b Hospital Prost jov   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; CREATININE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; PLACEBO; POTASSIUM; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PROSPECTIVE STUDY; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION; RESISTANT ARTERIAL HYPERTENSION; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BLOOD LEVEL; WEIGHT GAIN;

EID: 84919341348     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000162     Document Type: Article

References (38)

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51: 1403-1419.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-1080.
3. Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012; 14: 7-12.
4. Kumbhani DJ, Steg PG, Cannon CP, et al., REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013; 34: 1204-1214.
5. Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002; 15: 333-339.
6. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16: 925-930.
7. Sharabi Y, Adler E, Shamis A, et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006; 19: 750-755.
8. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007; 25: 891-894.
9. Chapman N, Dobson J, Wilson S, et al., Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007; 49: 839-845.
10. Václavík J, Kociánová E, TáborskÝ M. Use of spironolactone in the treatment of resistant arterial hypertension. Cor Vasa. 2011; 53: 343-347.
11. de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010; 55: 147-152.
12. Rodilla E, Costa JA, Pérez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol. 2009; 62: 158-166.
13. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens. 2010; 28: 2329-2335.
14. Association for the Advancement of Medical Instrumentation. American National Standard. Electronic or Automated Sphygmomanometers. Arlington: AAMI; 1993.
15. Jansen PM, Danser AH, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009; 27: 680-691.
16. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) - study protocol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011; 155: 143-148.
17. Václavík J, Sedlák R, PlachÝ M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011; 57: 1069-1075.
18. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
19. O'Brien E, Waeber B, Parati G, et al., European Society of Hypertension Working Group on Blood Pressure Monitoring. Blood pressure measuring devices: recommendations of the European Society of Hypertension. Brit Med J. 2001; 322: 531-536.
20. O'Brien E, Asmar R, Beilin L, et al., European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005; 23: 697-701.
21. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93: 3266-3281.
22. Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens. 2007; 25: 747-750.
23. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013; 31: 2094-2102.
24. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005; 18: 50-55.
25. Hansen TW, Li Y, Boggia J, et al. Predictive role of the nighttime blood pressure. Hypertension. 2011; 57: 3-10.
26. Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010; 8: CD008169.
27. Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011; 29: 980-990.
28. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005; 46: 481-487.
29. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008; 2: 462-468.
30. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30: 418-424.
31. Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens. 2010; 28: 170-177.
32. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009; 54: 475-481.
33. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentanresistant hypertension trial. Hypertension. 2010; 56: 824-830.
34. Symplicity HTN-2 InvestigatorsEsler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet. 2010; 376: 1903-1909.
35. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012; 30: 1047-1055.
36. Vaclavik J, Sedlak R, Jarkovsky J, et al. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157: 50-55.
37. Vaclavik J, Sedlak R, Jarkovsky J, et al. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 158: 384-390.
38. Bhatt DL, Kandzari DE, O'Neill WW, et al., SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393-1401.